Drug intelligence / Profile preview

pneumococcal 10-valent conjugate vaccine

Development stage
Unknown
Lead developer
Serum Institute of India
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

Pneumococcal vaccine (10-valent) is a conjugate vaccine designed to provide active immunization against invasive disease, pneumonia, and acute otitis media caused by *Streptococcus pneumoniae*. The most prominent version, Synflorix (developed by GSK), contains capsular polysaccharides from 10 specific serotypes (1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F), each conjugated to a carrier protein such as non-typeable *Haemophilus influenzae* Protein D, tetanus toxoid, or diphtheria toxoid. By conjugating the polysaccharides to proteins, the vaccine induces a T-cell dependent immune response, which is effective in infants and young children. It is typically administered as a multi-dose series in the first two years of life. Another 10-valent vaccine, Pneumosil (developed by the Serum Institute of India), targets a slightly different set of serotypes (1, 5, 6A, 6B, 7F, 9V, 14, 19A, 19F, and 23F).

Brand names
SynflorixPneumosil
Other names
PCV10PCV-10PCV 1010-valent pneumococcal conjugate vaccinepneumococcal vaccine (10-valent)
02

Targets

CPS (Streptococcus pneumoniae capsular polysaccharide)MHC class II-presented carrier-derived peptide / CD4+ T-cell receptor axisBCR (Immunoglobulin G B Cell Receptor)

Beyond the preview

Go deeper on pneumococcal 10-valent conjugate vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on pneumococcal 10-valent conjugate vaccine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call